Objective Acuity is a breakthrough digital health company that achieves early detection of vision and related disorders leading to changing lifelong healthcare and learning outcomes. There are many approaches to the measurement of vision and development disorders but all rely on a co-operative subject and are intrinsically subjective. Objective Acuity's first product is an objective measurement device that stimulates optokinetic nystagmus (OKN), an indicator of an intact vision pathway to determine poor vision. Clinical trials are about to get underway in children (200) and adults (120) to complete market validation, with a first market launch forecast for 2018.